Association between the expression of core 3 synthase and survival outcomes of patients with cholangiocarcinoma

Boottanun,Patcharaporn; Ino,Yoshinori; Shimada,Kazuaki; Hiraoka,Nobuyoshi; Angata,Kiyohiko; Narimatsu,Hisashi

doi:10.3892/ol.2021.13021

Association between the expression of core 3 synthase and survival outcomes of patients with cholangiocarcinoma

Authors:
- Patcharaporn Boottanun
- Yoshinori Ino
- Kazuaki Shimada
- Nobuyoshi Hiraoka
- Kiyohiko Angata
- Hisashi Narimatsu
View Affiliations

Affiliations: Graduate School of Comprehensive Human Sciences, Major in Medical Sciences, Clinical Sciences Program, Faculty of Medicine, University of Tsukuba, Tsukuba, Ibaraki 305‑8575, Japan, Division of Molecular Pathology, National Cancer Center Research Institute, Chuo‑ku, Tokyo 104‑0045, Japan, Hepatobiliary and Pancreatic Surgery Division, National Cancer Center Hospital, Chuo‑ku, Tokyo 104‑0045, Japan, Molecular and Cellular Glycoproteomics Research Group, Department of Life Science and Biotechnology, Cellular and Molecular Biotechnology Research Institute, National Institute of Advanced Industrial Science and Technology, Tsukuba, Ibaraki 305‑8565, Japan
Published online on: September 3, 2021 https://doi.org/10.3892/ol.2021.13021
Article Number: 760
Copyright: © Boottanun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cholangiocarcinoma (CCA) is a highly aggressive and metastatic type of malignant carcinoma that is associated with high mortality rates and is difficult to detect at early stages. Core 3 structure is a mucin‑type O‑glycans synthesized by β1,3‑N‑acetylglucosaminyltransferase 6 (core 3 synthase), which plays an important role in the digestive system, in particular gastrointestinal goblet cells. It has been reported that core 3 synthase‑expressing cells show lower migratory and invasive rates, and lower metastatic activity. A immunohistochemical study also showed that this enzyme was expressed in normal epithelial cells of the colon, but completely disappeared in colorectal cancer cells. The present study aimed to identify biomarkers that could be used to predict the prognosis of patients with CCA. Pathological specimens of 185 CCA tissues were immunohistochemically stained with two antibodies, G8‑144 and MECA‑79, which recognize core 3 synthase and 6‑sulfated N‑acetyllactosamine on the extended core‑1 O‑glycans, respectively. The association between G8‑144 or MECA‑79 positivity and patient prognosis was statistically analyzed. Positive expression of G8‑144 was associated with improved prognosis in patients with distal CCA (dCCA). Patients with dCCA positive for G8‑144 showed lower mortality rates than those with negative expression. However, the positive expression of MECA‑79 was associated with CCA progression and metastasis, indicating that it is a poor prognostic marker for CCA. In conclusion, as both antibodies resulted in mirror‑image staining, the involvement of G8‑144 and MECA‑79 in O‑glycan synthesis could be considered as potential favorable and unfavorable biomarkers, respectively, for CCA prognosis.

View Figures

View References

1	Cancer International Agency for Research on Cancer, . Cancer fact sheets. Cancer Today International Agency for Research on Cancer. World Health Organization; 2020
2	Nagtegaal ID, Odze RD and Klimstra D: WHO Classification of Tumours, Digestive System. International Agency for Research on Cancer. Wiley-Blackwell; Lyon: 2019
3	Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, et al: AJCC Cancer Staging Manual. Springer International Publishing; New York, NY: 2017, View Article : Google Scholar
4	Brierley JD, Gospodarowicz MK and Wittekind C; Union for International Cancer Control, : TNM Classification of Malignant Tumours. John Wiley & Sons, Inc.; Oxford, UK: 2017
5	Kamsa-Ard S, Luvira V, Suwanrungruang K, Kamsa-Ard S, Luvira V, Santong C, Srisuk T, Pugkhem A, Bhudhisawasdi V and Pairojkul C: Cholangiocarcinoma trends, incidence, and relative survival in khon kaen, thailand from 1989 through 2013: A population-based cancer registry study. J Epidemiol. 29:197–204. 2019. View Article : Google Scholar : PubMed/NCBI
6	Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, et al: Cholangiocarcinoma 2020: The next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 17:557–588. 2020. View Article : Google Scholar : PubMed/NCBI
7	Dodson RM, Weiss MJ, Cosgrove D, Herman JM, Kamel I, Anders R, Geschwind JF and Pawlik TM: Intrahepatic cholangiocarcinoma: Management options and emerging therapies. J Am Coll Surg. 217:736–750.e4. 2013. View Article : Google Scholar : PubMed/NCBI
8	Stowell SR, Ju T and Cummings RD: Protein glycosylation in cancer. Ann Rev Pathol. 10:473–510. 2015. View Article : Google Scholar : PubMed/NCBI
9	Varki A, Cummings RD, Esko JD, Stanley P, Hart GW, Aebi M, Darvill AG, Kinoshita T, Packer NH, Prestegard JH, et al: Essentials of Glycobiology. 3rd edition. Cold Spring Harbor Laboratory Press; Cold Spring Harbor, NY: 2015-2017
10	Iwai T, Kudo T, Kawamoto R, Kubota T, Togayachi A, Hiruma T, Okada T, Kawamoto T, Morozumi K and Narimatsu H: Core 3 synthase is down-regulated in colon carcinoma and profoundly suppresses the metastatic potential of carcinoma cells. Proc Natl Acad Sci USA. 102:4572–4457. 2005. View Article : Google Scholar : PubMed/NCBI
11	Iwai T, Inaba N, Naundorf A, Zhang Y, Gotoh M, Iwasaki H, Kudo T, Togayachi A, Ishizuka Y, Nakanishi H and Narimatsu H: Molecular cloning and characterization of a novel UDP-GlcNAc: GalNAc-peptide beta1,3-N Acetylglucosaminyltransferase (beta 3Gn-T6), an Enzyme Synthesizing the Core 3 Structure of O-Glycans. J Biol Chem. 277:12802–12809. 2002. View Article : Google Scholar : PubMed/NCBI
12	Lee SH, Hatakeyama S, Yu SY, Bao X, Ohyama C, Khoo KH, Fukuda MN and Fukuda M: Core3 O-Glycan synthase suppresses tumor formation and metastasis of prostate carcinoma PC3 and LNCaP cells through Down-regulation of alha2bata1 Integrin Complex. J Biol Chem. 284:17157–17169. 2009. View Article : Google Scholar : PubMed/NCBI
13	Ye J, Wei X, Shang Y, Pan Q, Yang M, Tian Y, He Y, Peng Z, Chen L, Chen W and Wang R: Core 3 mucin-type O-glycan restoration in colorectal cancer cells promotes MUC1/p53/miR-200c-dependent epithelial identity. Oncogene. 36:6391–6407. 2017. View Article : Google Scholar : PubMed/NCBI
14	Pearce OMT: Cancer glycan epitopes: Biosynthesis, structure and function. Glycobiology. 28:670–696. 2018. View Article : Google Scholar : PubMed/NCBI
15	Springer GF, Desai PR and Banatwala I: Blood group MN specific substances and precursors in normal and malignant human breast tissues. Naturwissenschaften. 61:457–458. 1974. View Article : Google Scholar : PubMed/NCBI
16	Springer GF: T and Tn, general carcinoma autoantigens. Science. 224:1198–1206. 1984. View Article : Google Scholar : PubMed/NCBI
17	Chia J, Goh G and Bard F: Short O-GalNAc glycans: Regulation and role in tumor development and clinical perspectives. Biochim Biophys Acta. 1860:1623–1639. 2016. View Article : Google Scholar : PubMed/NCBI
18	Hagisawa S, Ohyama C, Takahashi T, Endoh M, Moriya T, Nakayama J, Arai Y and Fukuda M: Expression of core 2 beta1, 6-N-acetylglucosaminyltransferase facilitates prostate cancer progression. Glycobiology. 15:1016–1024. 2005. View Article : Google Scholar : PubMed/NCBI
19	Brockhausen I: Mucin-type O-glycans in human colon and breast cancer: Glycodynamics and functions. EMBO Rep. 7:599–604. 2006. View Article : Google Scholar : PubMed/NCBI
20	Yeh JC, Hiraoka N, Petryniak B, Nakayama J, Ellies LG, Rabuka D, Hindsgaul O, Marth JD, Lowe JB and Fukuda M: Novel sulfated lymphocyte homing receptors and their control by a core1 extension beta 1,3-N-Acetylglucosaminyltransferase. Cell. 105:957–969. 2001. View Article : Google Scholar : PubMed/NCBI
21	Proteomics, . Tissue-based map of the human proteome. Science. 347:12604192015.https://www.proteinatlas.org/ENSG00000198488-B3GNT6July 23–2021 View Article : Google Scholar : PubMed/NCBI
22	Angata K, Sawaki H, Tsujikawa S, Ocho M, Togayachi A and Narimatsu H: Glycogene expression profiling of hepatic cells by RNA-Seq analysis for Glyco-biomarker identification. Front Oncol. 10:12242020. View Article : Google Scholar : PubMed/NCBI
23	Ino Y, Yamazaki-Itoh R, Oguro S, Shimada K, Kosuge T, Zavada J, Kanai Y and Hiraoka N: Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancer. PLoS One. 8:e551462013. View Article : Google Scholar : PubMed/NCBI
24	Doi N, Ino Y, Angata K, Shimada K, Narimatsu H and Hiraoka N: Clinicopathological significance of core 3 O-glycan synthetic enzyme, β1,3-N-acetylglucosaminyltransferase 6 in pancreatic ductal adenocarcinoma. PLoS One. 15:e02428512020. View Article : Google Scholar : PubMed/NCBI
25	Pinho SS and Reis CA: Glycosylation in cancer: Mechanisms and clinical implications. Nat Rev Cancer. 15:540–555. 2015. View Article : Google Scholar : PubMed/NCBI
26	Radhakrishnan P, Grandgenett PM, Mohr AM, Bunt SK, Yu F, Chowdhury S and Hollingsworth MA: Expression of core 3 synthase in human pancreatic cancer cells suppresses tumor growth and metastasis. Int J Cancer. 133:2824–2833. 2013.PubMed/NCBI
27	Fu C, Zhao H, Wang Y, Cai H, Xiao Y, Zeng Y and Chen H: Tumor-associated antigens: Tn antigen, sTn antigen, and T antigen. HLA. 88:275–286. 2016. View Article : Google Scholar : PubMed/NCBI
28	Ju T, Wang Y, Aryal RP, Lehoux SD, Ding X, Kudelka MR, Cutler C, Zeng J, Wang J, Sun X, et al: Tn and sialyl-Tn antigens, aberrant O-glycomics as human disease markers. Proteomics Clin Appl. 7:618–631. 2013. View Article : Google Scholar : PubMed/NCBI
29	Okayama H, Kumamoto K, Saitou K, Hayase S, Kofunato Y, Sato Y, Miyamoto K, Nakamura I, Ohki S, Koyama Y, et al: Ectopic expression of MECA-79 as a novel prognostic indicator in gastric cancer. Cancer Sci. 102:1088–1094. 2011. View Article : Google Scholar : PubMed/NCBI
30	Steentoft C, Yang Z, Wang S, Ju T, Vester-Christensen MB, Festari MF, King SL, Moremen K, Larsen ISB, Goth CK, et al: A validated collection of mouse monoclonal antibodies to human glycosyltransferases functioning in mucin-type O-glycosylation. Glycobiology. 29:645–656. 2019. View Article : Google Scholar : PubMed/NCBI
31	Dondossola D, Ghidini M, Grossi F, Rossi G and Foschi D: Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma. World J Gastroenterol. 26:3542–3561. 2020. View Article : Google Scholar : PubMed/NCBI
32	Aryal RP, Ju T and Cummings RD: The endoplasmic reticulum chaperone cosmc directly promotes in vitro folding of T-synthase. J Biol Chem. 285:2456–2462. 2010. View Article : Google Scholar : PubMed/NCBI
33	Gupta R, Leon F, Rauth S, Batra SK and Ponnusamy MP: A systematic review on the implications of O-linked glycan branching and truncating enzymes on cancer progression and metastasis. Cells. 9:4462020. View Article : Google Scholar : PubMed/NCBI
34	Hoshino H, Ohta M, Ito M, Uchimura K, Sakai Y, Uehara T, Low S, Fukushima M and Kobayashi M: Apical membrane expression of distinct sulfated glycans represents a novel marker of cholangiolocellular carcinoma. Lab Invest. 96:1246–1255. 2016. View Article : Google Scholar : PubMed/NCBI